Trials Today

A Study to Learn How Different Amounts of the Study Medicine Called PF-07314470 Are Tolerated and Act in the Body in Healthy Adults

Purpose

The purpose of this clinical trial is to learn if the study medicine (called PF-07314470) is safe and how it gets in and out of the body in healthy people.

Condition

Healthy

Eligibility

Eligible Ages: Between 18 Years and 55 Years
Eligible Sex: All
Accepts Healthy Volunteers: Yes

Inclusion Criteria

Healthy males aged 18 to 45 years and healthy females aged 18 to 55 years - Body Mass Index (BMI) of 16-32 kg/m2, and a total body weight greater than 50 kg (110 lb); for Japanese participants only, a total body weight greater than 45 kg - for Japanese participants only, enrolling as Japanese must have 4 biological grandparents who were born in Japan.

Exclusion Criteria

Evidence or history of clinically significant medical or psychiatric conditions - Prior or current use of any prohibited medications - History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence within 6 months of screening - Pregnant or breastfeeding females, males with partners currently pregnant, or males or females pursuing artificial reproductive technologies - Use of tobacco/nicotine containing products

Study Design

Phase: Phase 1
Study Type: Interventional
Allocation: Randomized
Intervention Model: Sequential Assignment
Primary Purpose: Other
Masking: Triple (Participant, Care Provider, Investigator)

Arm Groups

Arm	Description	Assigned Intervention
Experimental PF-07314470; Cohorts 1 to 7, optional Cohort 8 and optional Japanese Cohort 14	Participants will receive a single dose of PF-07314470 at 1 of 7 dose levels	Biological: PF-07314470 subcutaneous injection
Placebo Comparator Placebo for PF-07314470; Cohorts 1 to 7, optional Cohort 8 and optional Japanese Cohort 14	Participants will receive a single dose of placebo for PF-07314470	Biological: Placebo for PF-07314470 subcutaneous injection
Experimental PF-07314470; Cohorts 9 to 13	Participants will receive PF-07314470 weekly at 1 of 4 dose levels for 4 doses, or every 2 weeks at 1 dose level for 3 doses.	Biological: PF-07314470 subcutaneous injection
Placebo Comparator Placebo for PF-07314470; Cohorts 9 to 13	Participants will receive placebo for PF-07314470 weekly for 4 doses, or every 2 weeks for 3 doses.	Biological: Placebo for PF-07314470 subcutaneous injection

Recruiting Locations

More Details

NCT ID: NCT06821750
Status: Terminated
Sponsor: Pfizer

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.